Specialized Medical Company: Strong Q3 growth, margin expansion, and major expansion projects drive robust 2025 outlook

About this update from Specialized Medical Company

Q3 2025 saw strong revenue and profit growth, driven by a strategic shift to acute and outpatient services, with EBITDA margin rising to 27.3%. Expansion continues with new clinics and hospitals, a SAR 200 million special dividend, and robust guidance for year-end.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Specialized Medical Company